Provided by Tiger Trade Technology Pte. Ltd.

Palisade Bio Inc.

1.35
-0.1000-6.90%
Pre-market: 1.400.0500+3.70%04:00 EDT
Volume:4.77M
Turnover:6.54M
Market Cap:234.90M
PE:-6.70
High:1.46
Open:1.44
Low:1.32
Close:1.45
52wk High:2.86
52wk Low:0.9631
Shares:174.00M
Float Shares:130.00M
Volume Ratio:1.04
T/O Rate:3.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2015
EPS(LYR):-0.3014
ROE:-51.37%
ROA:-32.98%
PB:1.93
PE(LYR):-4.48

Loading ...

Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI)

TIPRANKS
·
May 13

Palisade Bio Inc - May Offer and Sell up to $300 Mln of Securities - SEC Filing

THOMSON REUTERS
·
May 13

Palisade Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate

Benzinga Earnings
·
May 13

Palisade Bio Q1 net loss widens on higher R&D costs

Reuters
·
May 13

Palisade Bio plans Phase 2 ulcerative colitis trial of PALI-2108 in Q3 2026

Reuters
·
May 13

BRIEF-Palisade Bio Q1 EPS USD -0.05

Reuters
·
May 13

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of Pali-2108

THOMSON REUTERS
·
May 13

Palisade Bio Q1 Operating Expenses USD 10.748 Million

THOMSON REUTERS
·
May 13

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

GlobeNewswire
·
May 13

Palisade Bio Q1 FY26 net loss widens to $9.6 million; operating loss widens to $10.75 million

Reuters
·
May 13

Palisade Bio Inc expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
May 09

Palisade Bio Phase 1a/b data show PALI-2108 supports once-daily ulcerative colitis dosing

Reuters
·
May 05

Palisade Bio Reports Additional Phase 1a/B Data Demonstrating Colon-Targeted Exposure and Sustained Ic90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

THOMSON REUTERS
·
May 05

Palisade Bio announces annual shareholder meeting

Reuters
·
Apr 18

Palisade Bio says PALI-2108 Phase 1 ulcerative colitis data set for DDW poster

Reuters
·
Apr 16

Piper Sandler Reaffirms Their Buy Rating on Palisade Bio (PALI)

TIPRANKS
·
Apr 13

Palisade Bio Initiated at Outperform by Wolfe Research

Dow Jones
·
Apr 10

Palisade Bio to present at Needham & Co. annual healthcare conference

Reuters
·
Apr 08

Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)

TIPRANKS
·
Apr 04